---
title: "GLORIA PHARMA. and Xinghe Pharmaceutical signed a joint promotion agreement for Pemabertinib tablets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241821403.md"
description: "GLORIA PHARMA and Xinghe Pharmaceutical signed a \"Joint Promotion Agreement\" to jointly promote Pemafibrate Tablets (brand name: Pailongda), with the agreement taking effect on June 1, 2025. Pemafibrate Tablets are the world's first novel highly selective PPARα modulator, aimed at reducing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. This collaboration will enrich GLORIA PHARMA's product pipeline, is expected to increase revenue and profits, and enhance competitiveness in the cardiovascular field"
datetime: "2025-05-26T09:29:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241821403.md)
  - [en](https://longbridge.com/en/news/241821403.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241821403.md)
---

# GLORIA PHARMA. and Xinghe Pharmaceutical signed a joint promotion agreement for Pemabertinib tablets

According to the Zhitong Finance APP, GLORIA PHARMA (002437.SZ) announced that the company has signed a "Joint Promotion Agreement" with Xinghe Pharmaceutical (China) Co., Ltd. (referred to as "Xinghe Pharmaceutical") for "Pemafibrate Tablets" (brand name: Palonida). The agreement will take effect on June 1, 2025.

Regarding the product under the agreement, Pemafibrate Tablets (brand name: Palonida) are the world's first novel highly selective PPARα modulator, primarily acting by activating PPARα to regulate the gene expression of lipid metabolism, thereby reducing plasma triglyceride (TG) levels and increasing high-density lipoprotein cholesterol (HDL-C) levels.

It is reported that this cooperation will enrich the company's product pipeline, is expected to increase the company's operating income and profits, and enhance the company's competitiveness in the cardiovascular and cerebrovascular fields

### Related Stocks

- [002437.CN](https://longbridge.com/en/quote/002437.CN.md)

## Related News & Research

- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [ZAWYA: JA Resorts & Hotels announces strategic enhancements across its Dubai portfolio](https://longbridge.com/en/news/287173198.md)
- [09:45 ETTrax Surgical's New Suture Anchor System Implanted in First Patient](https://longbridge.com/en/news/286924374.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)